Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Siegel Discusses Accelerated Drug Approval

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

Dr. Siegel on Biomarkers and Molecular Analysis

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

Dr. Siegel on His Presentation at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. Siegel on the Practice Changes the Past 10 Years

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

Dr. Siegel on Drugs Discussed at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. Siegel on the Carfilzomib FDA Approval Process

March 14th 2011

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

Dr. Siegel on the Importance of Bisphosphonates

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

Intensive Chemotherapy Boosts Prognosis in Older Teens With Acute Lymphoblastic Leukemia

March 13th 2011

New data demonstrate that older adolescents with acute lymphoblastic leukemia (ALL) can be cured using risk-adjusted intensive chemotherapy without prophylactic cranial irradiation or routine stem cell transplantation.

The Aggressive Peripheral T-Cell Lymphomas

March 13th 2011

The aggressive peripheral T-cell lymphomas make up less than 10% of all lymphomas diagnosed each year in the United States.

Crisis Averted? Manufacturers Scurry to Meet Demand for Drugs

March 12th 2011

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

Net Guides: Non-Hodgkin Lymphoma

March 10th 2011

Useful Online Resources and Clinical Trials for Non-Hodgkin Lymphoma

Net Guides: Acute Myelogenous Leukemia

March 10th 2011

Useful Online Resources and Clinical Trials for Acute Myelogenous Leukemia

ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL

March 10th 2011

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

ASH 2010: A New Scoring System Assesses the Risk of Recurrent Venous Thromboembolism

March 10th 2011

A new scoring system has been developed that is designed to predict the risk of recurrent venous thromboembolism (VTE) in a patient with cancer.

ASH 2010: Ponatinib Inhibits Mutations That Block Treatment Paths for CML, ALL, and AML

March 10th 2011

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

ASH 2010: Data Support Escalated BEACOPP as Superior Method of Tumor Control in Early Unfavorable Hodgkin Lymphoma

March 10th 2011

In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.

Do Breast Implants Increase Cancer Risk?

March 10th 2011

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

March 9th 2011

The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.

ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma

March 9th 2011

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.